Oxis Biotech, Inc. (Oxis)

Oncology Corporate Profile

HQ Location

4830 West Kennedy Blvd
Tampa, FL 33609

Company Description

Oxis Biotech is an immuno-oncology focused company developing innovative drugs focused on the treatment of cancer and other unmet medical needs. OXIS' lead drug candidate, OXS-1550 (DT2219ARL), is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors.

Website: http://www.oxis.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
OXS-1550bispecific scFv recombinant fusion proteinNon-Hodgkin's Lymphoma (NHL)I

View additional information on product candidates here »

Source


http://www.oxis.com

Recent News Headlines

OXIS Biotech Scientific Advisory Board Member to Address Cancer Immunotherapy Conference in China

3/21/2017 12:00 pm

[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / March 21, 2017 / Oxis International Inc. (OTCQB: OXIS) ( Euronext Paris OXI.PA ) announced today that Dr. Daniel Vallera, a member of the Scientific Advisory Board of its ...

Oxis Biotech Announces U.S. Patent and Trademark Office Notification of Patent Issuance for Oxis-4235 as Treatment for Multiple Myeloma

2/21/2017 01:01 pm

[Accesswire] - TAMPA, FL / ACCESSWIRE / February 21, 2017 / Oxis International, Inc. (OTCQB: OXIS) (OXIS.PA) parent company of Oxis Biotech, focused on the development and commercialization of immunotherapy for the treatment ...

Oxis Biotech Announces Enrollment of 2 New Patients in FDA Clinical Trial of Promising Cancer Drug OXS-1550

1/17/2017 01:01 pm

[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / January 17, 2017 / Oxis International Inc. , a biotechnology company focused on immunotherapies for the treatment of cancer, announced today that ...

OXIS' TriKE Cancer-Fighting Platform Receives Favorable News Coverage in Minneapolis Star-Tribune

10/4/2016 12:01 pm

[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / October 4, 2016 / Oxis International Inc. (OTCQB: OXIS and Euronext Paris OXI.PA ) announced today that its promising TriKE cancer-fighting platform was highlighted in the ...

Oxis Biotech to Discuss its Cancer-Fighting Platforms at Rodman & Renshaw Global Investment Conference

9/8/2016 12:01 pm

[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / September 8, 2016 / Oxis International Inc. (OTCQB: OXIS and Euronext Paris OXI.PA ) announced today that Anthony J. Cataldo, its Chief Executive Officer, will present a ...

Oxis International Comments On New York Times Article About Cancer Immunotherapy

8/29/2016 05:01 pm

[at noodls] - LOS ANGELES, CA / ACCESSWIRE / August 1, 2016 / Oxis International Inc. (OTCQB:OXIS and Euronext Paris OXI.PA), a company that has made significant strides in harnessing the immune system to fight cancer, ...

Oxis Biotech Scientific Advisory Board Member to Address World Summit on Cancer Research

8/29/2016 04:05 pm

[at noodls] - LOS ANGELES, CA / ACCESSWIRE / August 16, 2016 / Oxis International Inc. (OTCQB: OXIS and Euronext Paris OXI.PA) announced today that Dr. Daniel Vallera, a member of the Scientific Advisory Board of its ...

Oxis Biotech's TriKE Cancer-Fighting Technology Receives Key NIH Endorsement

8/29/2016 04:03 pm

[at noodls] - LOS ANGELES, CA / ACCESSWIRE / August 29, 2016 / Oxis Biotech Inc., a wholly owned subsidiary of Oxis International Inc. (OTCQB: OXIS and Euronext Paris OXI.PA), announced today that its research partners ...

Oxis Biotech's TriKE Cancer-Fighting Technology Receives Key NIH Endorsement

8/29/2016 11:03 am

[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / August 29, 2016 / Oxis Biotech Inc., a wholly owned subsidiary of Oxis International Inc. (OTCQB: OXIS and Euronext Paris OXI.PA ), announced today that its research partners ...

Oxis Biotech Scientific Advisory Board Member to Address World Summit on Cancer Research

8/16/2016 11:03 am

[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / August 16, 2016 / Oxis International Inc. (OTCQB: OXIS and Euronext Paris OXI.PA ) announced today that Dr. Daniel Vallera, a member of the Scientific Advisory Board of its ...